Chime Biologics, located in Wuhan’s Biotech Industry Development Zone, operates the world’s first GMP-grade GE KuBio modular bio-manufacturing facility. This state-of-the-art facility complies with global quality standards set by ICH, FDA, EMA, and NMPA.  

 

Leveraging its advanced infrastructure and extensive bio-manufacturing expertise, Chime Biologics offers comprehensive, integrated solutions to meet the dynamic needs of the biopharmaceutical industry. The company supports clients throughout the entire drug development process, from early-stage research to late-stage clinical trials and commercial cGMP production.  

 

In April 2021, Chime Biologics announced a $190 million Series A+ financing to accelerate capacity expansion, aiming to increase its total manufacturing capacity to over 140,000 liters within the next five years.  

 

Chime Biologics’ commitment to innovation and quality positions it as a leading Contract Development and Manufacturing Organization (CDMO) in the global biopharmaceutical sector.